M2696

Metyrapone

≥98% (HPLC), solid

• Synonym(s): 2-Methyl-1,2-di-3-pyridyl-1-propanone, Metyrapone, Su-4885
• Empirical Formula (Hill Notation): C₁₄H₁₄N₂O
• CAS Number: 54-36-4
• Molecular Weight: 226.27
• Beilstein: 163023
• EC Number: 200-206-2
• MDL number: MFCD00006397
• UNSPSC Code: 51111800
• PubChem Substance ID: 329817949
• NACRES: NA.77

Properties

• sterility: non-sterile
• Quality Level: 100
• Assay: ≥98% (HPLC)
• form: solid
• technique(s): toxicology assay: suitable
• mp: 52-55 °C (lit.)
• solubility: H₂O: <2 mg/mL; DMSO: >20 mg/mL
• originator: Novartis
• shipped in: ambient
• storage temp.: room temp
• SMILES string: CC(C)(c1cccnc1)C(=O)c2cccnc2
• InChI: 1S/C14H14N2O/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11/h3-10H,1-2H3
• InChI key: FJLBFSROUSIWMA-UHFFFAOYSA-N

Description

Biochem/physiol Actions

Metyrapone is a glucocorticoid synthesis inhibitor; a standard in assessing adrenal gland function especially in response to stress, as well as pituitary gland function. In addition to acting as a glucocorticoid synthesis inhibitor, Metyrapone also inhibits cytochrome P450-mediated prostaglandin ω/ω-1 hydroxylase activity and impairs learning and memory. Data shows results in activation of the sleep EEG and a robust decrease in quantitative delta sleep.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Safety Information

• Pictograms: GHS07
• Signal Word: Warning
• Hazard Statements: H302,H315,H319,H335
• Precautionary Statements: P261 - P264 - P271 - P301 + P312 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• Target Organs: Respiratory system
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves